MX2024008273A - Composiciones y metodos para el tratamiento de la enfermedad de huntington. - Google Patents
Composiciones y metodos para el tratamiento de la enfermedad de huntington.Info
- Publication number
- MX2024008273A MX2024008273A MX2024008273A MX2024008273A MX2024008273A MX 2024008273 A MX2024008273 A MX 2024008273A MX 2024008273 A MX2024008273 A MX 2024008273A MX 2024008273 A MX2024008273 A MX 2024008273A MX 2024008273 A MX2024008273 A MX 2024008273A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- methods
- compositions
- treating huntington
- subject
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163295213P | 2021-12-30 | 2021-12-30 | |
| US202263349305P | 2022-06-06 | 2022-06-06 | |
| PCT/US2022/082523 WO2023130001A1 (en) | 2021-12-30 | 2022-12-29 | Compositions and methods for treating huntington's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008273A true MX2024008273A (es) | 2024-07-19 |
Family
ID=87000332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008273A MX2024008273A (es) | 2021-12-30 | 2022-12-29 | Composiciones y metodos para el tratamiento de la enfermedad de huntington. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250074973A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4457244A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025503545A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240126863A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022425559A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313901A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024008273A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023130001A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3019240T3 (da) * | 2013-07-09 | 2024-06-03 | Annexon Inc | Anti-komplementfaktor C1Q antistoffer og anvendelser deraf |
| EP3380518B1 (en) * | 2015-11-24 | 2026-03-25 | Annexon, Inc. | Anti-complement factor c1q fab fragments and uses thereof |
| GB2584105B (en) * | 2019-05-21 | 2023-08-02 | Argenx Bvba | Methods of treating neuropathy |
-
2022
- 2022-12-29 US US18/725,580 patent/US20250074973A1/en active Pending
- 2022-12-29 JP JP2024539560A patent/JP2025503545A/ja active Pending
- 2022-12-29 AU AU2022425559A patent/AU2022425559A1/en active Pending
- 2022-12-29 EP EP22917557.5A patent/EP4457244A4/en active Pending
- 2022-12-29 IL IL313901A patent/IL313901A/en unknown
- 2022-12-29 KR KR1020247023399A patent/KR20240126863A/ko active Pending
- 2022-12-29 MX MX2024008273A patent/MX2024008273A/es unknown
- 2022-12-29 WO PCT/US2022/082523 patent/WO2023130001A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4457244A4 (en) | 2026-01-07 |
| EP4457244A1 (en) | 2024-11-06 |
| US20250074973A1 (en) | 2025-03-06 |
| JP2025503545A (ja) | 2025-02-04 |
| AU2022425559A1 (en) | 2024-07-04 |
| IL313901A (en) | 2024-08-01 |
| KR20240126863A (ko) | 2024-08-21 |
| WO2023130001A1 (en) | 2023-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12021551734A1 (en) | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders | |
| NO20034549L (no) | Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV | |
| NO962568L (no) | Anvendelse av PLA2 inhibitorer som behandling for Alzheimers sykdom | |
| BR0304648A (pt) | Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia | |
| EA202092750A1 (ru) | Соединения ингибиторы vmat2, композиции и способы, относящиеся к ним | |
| WO2022047128A3 (en) | Method for treating complement mediated disorders caused by betacoronaviruses | |
| BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
| ECSP20082339A (es) | Moduladores de la expresión de apol1 | |
| MX2024003120A (es) | Metodos y composiciones que comprenden anticuerpos anti-cd3 e inhibidores de dyrk1a para tratar la diabetes. | |
| WO2022081813A3 (en) | Enhanced scale inhibitor squeeze treatment using a chemical additive | |
| ZA202106809B (en) | Medium chain triglyceride formulations with improved bioavailiblity and methods related thereto | |
| MX2024014121A (es) | Metodos y composiciones para el tratamiento del exceso de glucocorticoides | |
| MX2022010258A (es) | Composiciones y métodos para tratar la lesión renal. | |
| MX2022011725A (es) | Metodos para tratar una lesion pulmonar con inhibidores de cgrp. | |
| WO2023055885A3 (en) | Ezh2 inhibition in pancreatic cancer | |
| MX2024015763A (es) | Composiciones y metodos para inhibir la expresion de serina proteasa transmembrana 6 (tmprss6) | |
| MX2022012632A (es) | Uso de inhibidores del bromodominio para el tratamiento de la enfermedad de huntington. | |
| MX2024008273A (es) | Composiciones y metodos para el tratamiento de la enfermedad de huntington. | |
| CA3242780A1 (en) | Compositions and methods for treating huntington's disease | |
| MX2022013927A (es) | Composiciones y metodos para tratar la epilepsia. | |
| WO2023147513A3 (en) | Compositions of autophagy modulating agents and uses thereof | |
| CL2022002317A1 (es) | Métodos para tratar esclerosis múltiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. | |
| WO2025030161A8 (en) | Rexinoids for treatment of ocular diseases | |
| PH12022552645A1 (en) | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases | |
| FR3108031B1 (fr) | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur dorsale et compositions correspondantes |